NIKKEI 225
38,236.07 -37.98 (-0.10%) HANG SENG
18,207.13 +444.10 (+2.50%) CRUDE OIL
79.13 +0.18 (+0.23%) GOLD FUTURES
2,314.00 +4.40 (+0.19%) DOW
38,225.66 +322.37 (+0.85%) Bitcoin GBP
47,251.52 +1,054.48 (+2.28%)
BioSenic S.A. (0R55.L)
| Previous close | 0.0146 |
| Open | 0.0148 |
| Bid | 0.0000 x N/A |
| Ask | 0.0000 x N/A |
| Day's range | 0.0139 - 0.0148 |
| 52-week range | 0.0139 - 0.1890 |
| Volume | |
| Avg. volume | 12,067 |
| Market cap | 1,512 |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
BioSenic S.A. : Information on the total number of voting rights and shares
PRESS RELEASE – REGULATED INFORMATION Mont-Saint-Guibert, Belgium, April 30, 2024, 7.00 am CEST – BIOSENIC (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune and inflammatory diseases and cell therapy, today announces an increase in the total number of voting rights and shares as a result of the issuance of new shares. The following information is published in accordance with Article 15 of the Belgian law of 2 May 2007 on the publication of major s
- Globe Newswire
BioSenic publishes on its website the restructuring plan submitted to the Enterprise Court of Nivelles
PRESS RELEASE - PRIVILEGED INFORMATION Mont-Saint-Guibert, Belgium, 26 April 2024, 17:30 CET – BioSenic (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune and inflammatory diseases, as part of the global restructuring plan announced on 11 April 2024, today announces the publication on its website of the following documentation : The restructuring plan covering the years 2024-2030 submitted to the Enterprise Court of Nivelles – accessible via the fo
- Globe Newswire
BioSenic postpones its annual general meeting of the shareholders and provides temporary non-audited financial figures for 2023
PRESS RELEASE - PRIVILEGED INFORMATION In view of the restructuring plan announced on April 11, 2024, BioSenic has decided to postpone the publication of its 2023 annual report as well as its annual general meeting of shareholders, so that the Enterprise Court of Nivelles can make a decision before the completion of the annual formalities. The Company believes that this postponement is preferable to ensure that the financial statements can be prepared on a going concern basis. Mont-Saint-Guibert
